BDSX vs MYGN
BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies. MYGN: Myriad Genetics is a molecular diagnostics and precision medicine company that develops genetic tests for cancer screening, therapy selection, prenatal health, and mental health to guide clinical decisions and improve patient outcomes.
Side-by-side fundamentals
| Metric | BDSX | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.39 | $5.66 | |
| Market cap as of 2026-07-23 | $222M | $547M | |
| PEG as of 2026-07-23 | n/a | -0.00 | |
| Net margin as of 2026-07-23 | -33.3% | -48.2% | BDSX higher |
| Gross margin as of 2026-07-23 | +82.1% | +70.0% | BDSX higher |
| Operating margin as of 2026-07-23 | -25.9% | -46.9% | BDSX higher |
| ROE as of 2026-07-23 | -375.1% | -109.1% | MYGN higher |
| ROA as of 2026-07-23 | -35.6% | -57.4% | BDSX higher |
| Debt / equity as of 2026-07-23 | 5.09 | 0.36 | MYGN lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.1% | -0.3% | BDSX higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | +6.7% | BDSX higher |
| Beta as of 2026-07-23 | 0.58 | 1.62 | |
| 1-year return as of 2026-07-22 close | +202.0% | +23.3% | BDSX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.